Supported by grants CA76489 and CA012582 from the National Institutes of Health, National Cancer Institute, and by funding from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Cancer Institute or the National Institutes of Health. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The trial was also funded by CancerVax Corporation, Carlsbad, CA.
Collaborators of the MMAIT-IV Clinical Trial Group
John F. Thompson, MD (Royal Prince Alfred Hospital, Sydney, Australia); Mark Smithers, MB, BS (Princess Alexandra Hospital, Brisbane, Australia); Michael Hughes, MBBS (Westmead Hospital, Westmead, Australia); Brendon J. Coventry, MB, BS, PhD (Royal Adelaide Hospital, Adelaide, Australia); Jeremy Shapiro, MBBS (Alfred Hospital, Melbourne, Australia); Grant McArthur, MBBS, PhD (Peter MacCallum Cancer Centre, Melbourne, Australia); Antonio Buzaid, MD (Hospital Sirio Libanes, Sao Paulo, Brazil); Wilson Miller, MD (McGill University, Montreal, Quebec, Canada); Dirk Schadendorf, MD (University Hospital of Mannheim, Mannheim, Germany); Claus Garbe, MD (University of Tuebingen, Tuebingen, Germany); Martin Kaatz, MD (University of Jena, Jena, Germany); Ralf Uwe Peter, MD, PhD (University of Ulm, Ulm, Germany); Patrick Terheyden, MD (University Hospital Wuerzburg, Wuerzburg, Germany); Angus Dalgleish, MD (St. George’s Hospital Medical School, London, Great Britain); Paul Redmond, MD (Cork University Hospital, Cork, Ireland); Schlomo Schneebaum, MD (Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel); Nicola Mozzillo, MD (Istituto Nazionale dei Tumori de Napoli, Naples, Italy); Alessandro Testori, MD (Istituto Europeo Di Oncologia, Milan, Italy); Mario Santinami, MD (Istituto Nazionale dei Tumori-Milano, Milan, Italy); Harald J. Hoekstra, MD, PhD (University Medical Center Groningen and University of Groningen, Groningen, The Netherlands); Michael McCrystal, MD (North Shore Hospital, Auckland, New Zealand); Reinhard Dummer, MD (University of Zurich, Zurich, Switzerland); Mohammed Kashani-Sabet, MD (University of California, San Francisco, Mt. Zion Medical Center, CA, USA); Mark C. Kelley, MD (Vanderbilt University, Nashville, TN, USA); Ronald DeConti, MD (H. Lee Moffitt Cancer Center, Tampa, FL, USA); Jeffrey Lee, MD (MD Anderson Cancer Center, Houston, TX, USA); James F. Huth, MD (University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA); Mark Faries, MD (John Wayne Cancer Institute, Santa Monica, CA, USA); Jeffrey Wagner, TX (Wagner, Wagner & Associates, Indianapolis, IN, USA); Evan Hersh, MD (Arizona Cancer Center, Tucson, AZ, USA); Clay Anderson, MD (University of Missouri, Columbia, MO, USA); Kelly McMasters, MD (University of Louisville, Louisville, KY, USA); Lynn Schuchter, MD (University of Pennsylvania Cancer Center, Philadelphia, PA, USA); Constantine P. Karakousis, MD, PhD (Millard Fillmore Hospital, Buffalo, NY, USA); William Kraybill, MD (Roswell Park Cancer Institute, Buffalo, NY, USA); Rene Gonzalez, MD (University of Colorado Cancer Center, Aurora, CO, USA); David Byrd, MD (University of Washington, Seattle, WA, USA); David Ollila, MD (University of North Carolina-Chapel Hill, Chapel Hill, NC, USA); Michael Walker, MD (Ohio State University, Columbus, OH, USA); Ernest Borden, MD (Cleveland Clinic Foundation, Cleveland, OH, USA); Marie-France Demierre, MD (Boston Medical Center, Boston, USA); Dirk Noyes, MD (IHC Cancer Services-LDS Hospital, Salt Lake City, UT, USA); Douglas Reintgen, MD (Lakeland Regional Cancer Center, Lakeland, FL, USA); Lee Riley, MD (St. Luke’s Hospital Cancer Center, Bethlehem, PA, USA); Kathy Yao, MD (Loyola University Medical Center, Chicago, IL, USA); Howard Kaufman, MD (Columbia University, New York, NY, USA); Philip Leming, MD (Christ Hospital, Cinncinnati, OH, USA); Edward Levine, MD (Wake Forest University, Winston-Salem, NC, USA); Neal Ready, MD (BrUOG-Rhode Island Hospital, Providence, RI, USA); Gregory Sarna, MD (Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, USA); William Sharfman, MD (Sidney Kimel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA); Robert Dillman, MD (Hoag Cancer Center, Huntington Beach, CA, USA); Norman Estes, MD (OSF Saint Francis Medical Center, Peoria, IL, USA); Laura Hutchins, MD (University of Arkansas for Medical Sciences (UAMS), Little Rock, AK, USA); Andrew Pecora, MD (Hackensack University Medical Center, Hackensack, NJ, USA); John Richart, MD (St. Louis University Health Sciences Center, St. Louis, MO, USA); Neal Rothschild, MD (Palm Beach Cancer Institute, West Palm Beach, FL, USA); John Vetto, MD (Oregon Health Sciences University, Portland, OR, USA); Harold Wanebo, MD (BrUOG-Roger Williams Hospital, Providence, RI, USA); Michael Warso, MD (University of Illinois at Chicago, Chicago, IL, USA); Ned Carp, MD, PhD (Lankenau Hospital, Wynnewood, PA, USA); George Elias, MD (Franklin Square Hospital Center, Baltimore, MD, USA); Mark Greene, MD (Mayo Clinic Scottsdale, AZ, USA); David Hyams, MD (Comprehensive Cancer Center of the Desert, Palm Springs, CA, USA); Jose Lutzky, MD (Mt. Sinai Comprehensive Cancer Center, Miami Beach, FL, USA); Jonathan Polikoff, MD (Kaiser Hospital, Riverside, CA, USA); Armando Sardi, MD (St. Agnes Healthcare, Baltimore, MD, USA); Frank Senecal, MD (Northwest Medical Specialties, Tacoma, WA, USA).
Disclosures
Guy Gammon, Daniel Pertschuk and Christopher Nardo were employees of the CancerVax Corporation. Donald L. Morton was a stockholder and patent holder for CancerVax Corporation and Canvaxin, respectively. There are no other relelvant conflicts.